<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75547">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903044</url>
  </required_header>
  <id_info>
    <org_study_id>ICMI_ 404732/2012-7</org_study_id>
    <nct_id>NCT01903044</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating</brief_title>
  <official_title>Multicentric Study of the Autologous Bone Marrow-derived Mononuclear Cells Injection for Treatment of the Patients With Critical Lower Extremity Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Moléstias Cardiovasculares de São José do Rio Preto, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Geral Nacional Enrique Cabrera, Cuba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Hematología e Inmunología, Cuba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Araucária, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontifícia Universidade Católica do Paraná</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether autologous bone marrow-derived stem cells
      are effective in the treatment of lower extremity ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical limb ischemia (CLI) is a debilitating and disabling disease. Symptoms include pain
      at rest, loss of tissue integrity, distal amputations and have a major impact on the quality
      of life. Despite recent advances in surgical vascular procedures, a large number of patients
      (approximately 40%) are not eligible for these revascularization procedures. New strategies
      for revascularization need to be explored. Besides, in some cases results of such
      interventions do not give desirable effect, search of new methods of treatment therefore is
      necessary. Recent evidence indicates that bone marrow-derived mononuclear cells (BM-MNC) are
      a potential new therapeutic target.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome classification</measure>
    <time_frame>3 months, 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of symptoms, functional capacity, exercises tolerance assessed by change in Rutherford scale of CLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and analgesics use</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome</measure>
    <time_frame>3 months, 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the coronary and collateral circulation.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without amputation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lower Extremity Ischemia</condition>
  <condition>Leg Ulcer</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Diabetic Foot</condition>
  <condition>Gangrene</condition>
  <arm_group>
    <arm_group_label>BM-MNC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of autologous bone marrow-derived mononuclear cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BM-MNC injection</intervention_name>
    <description>BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles</description>
    <arm_group_label>BM-MNC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critical lower limb ischemia, defined as ischemic pain at rest and / or the presence
             of minor tissue loss, with the possibility of healing.

          -  Failure of conventional medical treatment and attempts to open or percutaneous
             revascularization before, with an observation period of two months after the last
             attempt at revascularization.

          -  Patients considered at high risk for new revascularization procedure by at least two
             independent observers.

        Exclusion Criteria:

          -  Expected life span less than six months

          -  Large tissue loss in the ischemic limb indicating the need for limb amputation in the
             short term.

          -  Evidence of osteomyelitis in the ischemic extremity.

          -  Current or previous history of neoplasia.

          -  Unstable angina, recent stroke or other medical condition that contraindicate
             anesthesia for bone marrow aspiration.

          -  Proliferative retinopathy.

          -  Debilitating disease with a life span less than one year.

          -  Myelofibrosis, myelodysplasia or other diseases that affect the bone marrow.

          -  Use of alcohol in excess of twice-daily doses or history of illicit drug use.

          -  Need for continuous high doses of drug therapy with steroids (more than 7.5 mg/day).

          -  Posivity for HIV or syphilis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Brofman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontifícia Universidade Católica do Paraná</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulo Brofman, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>paulo.brofman@pucpr.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Senegaglia, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>alexandra.senegaglia@pucpr.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pontifícia Universidade Católica do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80215-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Rebelatto, PhD</last_name>
      <phone>+55 41 3271 1858</phone>
      <email>carmen.rebelatto@pucpr.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 16, 2013</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontifícia Universidade Católica do Paraná</investigator_affiliation>
    <investigator_full_name>Danielle Malheiros</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Lowe extremity ischemia</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Neoangiogenesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gangrene</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
